The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

• Published in: Nature chemical biology Vol. 10; no. 9; pp. 768 - 773
• Main Authors: Winter, Georg E, Radic, Branka, Mayor-Ruiz, Cristina, Blomen, Vincent A, Trefzer, Claudia, Kandasamy, Richard K, Huber, Kilian V M, Gridling, Manuela, Chen, Doris, Klampfl, Thorsten, Kralovics, Robert, Kubicek, Stefan, Fernandez-Capetillo, Oscar, Brummelkamp, Thijn R, Superti-Furga, Giulio
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.09.2014; Nature Publishing Group
• Subjects: 45; 45/23; 45/91; 631/337/1427; 631/67; 631/80/82; 631/92/93; Animals; Apoptosis - drug effects; Biochemical Engineering; Biochemistry; Bioorganic Chemistry; Cancer therapies; Cell Biology; Cell Division - drug effects; Cell Division - physiology; Cell Line, Tumor; Cell Survival; Chemistry; Chemistry/Food Science; Chemotherapy; Cloning, Molecular; Comet Assay; Cytotoxicity; Deoxyribonucleic acid; DNA; DNA damage; DNA Damage - drug effects; Drug resistance; Genes; Genome, Human - drug effects; Genome, Human - genetics; Genomes; Haploidy; Humans; Imidazoles - metabolism; Imidazoles - pharmacology; Immunohistochemistry; Intercalating Agents - pharmacology; Medical research; Membrane Transport Proteins - genetics; Membrane Transport Proteins - metabolism; Mice; Mice, SCID; Mutagenesis; Mutation; Naphthoquinones - metabolism; Naphthoquinones - pharmacology; Proteins; RNA, Neoplasm - chemistry; RNA, Neoplasm - genetics; Toxicity; Netherlands

A haploid screen in human cells identified the solute carrier protein family member, SLC35F2, as a determinant of the sensitivity of cells to the DNA damaging agent, YM155, by promoting YM155 import into cells. Genotoxic chemotherapy is the most common cancer treatment strategy. However, its untarge...